Ironshore Pharmaceuticals & Development, Inc. has developed a novel oral, once-daily, drug delivery technology. DELEXIS has delayed-release properties that limit the release of the medication overnight and extended-release properties that control the release of the medication throughout the following day.› Learn More About DELEXIS
Our lead products are targeted at helping ADHD patients and their families by leveraging proprietary technologies to address a significant unmet medical need – inadequate control of symptoms of ADHD during the morning routine.
A majority of surveyed families report ADHD symptoms as ‘severe’ or ‘moderate-to-severe’ during the morning routine – the period immediately upon waking until the patient leaves for work or school. This period is often the busiest and most chaotic for families.
Ironshore has developed a proprietary, oral controlled-release technology for evening dosing of medication with delayed and extended release characteristics that is designed to provide for next-day therapeutic activity beginning in the early morning and lasting throughout the day.